Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Thyroid Neoplasms 1Recurrence 1Pancreatic Adenocarcinoma 1Histiocytosis 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Panitumumab × Clear all
NCT01504477 2020-03-16

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Georgetown University

Phase 1/2 Terminated
6 enrolled 8 charts
Gastrointestinal

Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡